China Equity Strategy: Domestic Funds Rush to Deploy Capital in Hong Kong Market
China mainland funds have accelerated their capital deployment in Hong Kong market in the new year. The fund inflow to Hong Kong has exceeded RMB...
527 Views
Wuxi Biologics (2269 HK) - A Monopoly in China Macromolecule CDMO
This article analyzed WuXi Biologics in terms of market potential and position, technology platforms & R&D capability, business analysis, and...
446 Views
ECM Weekly (10 January 2021) - RLX Technology, Roiserv, Yidu Tech, and Placements
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
522 Views
Aequitas 2020 IPOs and Placements Performance - IPOs in the Limelight but Placements Stole the Show
2020 marked our second year of operations as an Independent Research Company, and our fifth year covering ECM. In 2020 we had an accuracy rate of...
525 Views
Wuxi Biologics Placement - Well Ahead of Lock-Up, Again
Wuxi Biologics Holdings is looking to raise up to US$1bn by selling about 2% of Wuxi Biologics (Cayman) Inc (2269 HK).Ā This is the company's 12th...
526 Views